-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

Implications for Ongoing Clinical Research in SCD and Drug Development

Program: Special-Interest Sessions
Session: Clinical Care and Research Implications Following Voxelotor Withdrawal
Monday, December 9, 2024, 10:30 AM-12:00 PM

Maureen Okam Achebe, MD, MPH

Brigham and Women's Hospital, Harvard Medical School, Boston, MA

Disclosures: Achebe: Global Blood Therapeautics: Membership on an entity's Board of Directors or advisory committees; Pharmacosmos: Membership on an entity's Board of Directors or advisory committees; Vertex Pharmaceuticals: Membership on an entity's Board of Directors or advisory committees; Fulcrum: Membership on an entity's Board of Directors or advisory committees.

See more of: Clinical Care and Research Implications Following Voxelotor Withdrawal
See more of: Special-Interest Sessions
<< Previous Presentation | Next Presentation >>